Cargando…

A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial

AIM: To examine the adjunctive effect of a Lactobacillus reuteri probiotic (ATCC PTA 5289 & DSM 17938) on the re‐instrumentation of residual pockets. MATERIALS AND METHODS: This randomized, double‐blind, placebo‐controlled study included 39 previously non‐surgically treated periodontitis patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Laleman, Isabelle, Pauwels, Martine, Quirynen, Marc, Teughels, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973056/
https://www.ncbi.nlm.nih.gov/pubmed/31520543
http://dx.doi.org/10.1111/jcpe.13198
_version_ 1783489965819166720
author Laleman, Isabelle
Pauwels, Martine
Quirynen, Marc
Teughels, Wim
author_facet Laleman, Isabelle
Pauwels, Martine
Quirynen, Marc
Teughels, Wim
author_sort Laleman, Isabelle
collection PubMed
description AIM: To examine the adjunctive effect of a Lactobacillus reuteri probiotic (ATCC PTA 5289 & DSM 17938) on the re‐instrumentation of residual pockets. MATERIALS AND METHODS: This randomized, double‐blind, placebo‐controlled study included 39 previously non‐surgically treated periodontitis patients. A re‐instrumentation was carried out, and probiotic and/or placebo drops were applied according to the study protocoll. Patients afterwards received lozenges to use 2×/day for 12 weeks. Probing pocket depth (PPD), recession, bleeding on probing and plaque levels were analysed, next to the microbiological impact. RESULTS: No effects of the probiotic drops could be found. However, after 24 weeks, the overall PPD in the probiotic lozenges group (2.64 ± 0.33 mm) was significantly lower compared to the control lozenges (2.92 ± 0.42 mm). This difference was even more pronounced in moderate (4–6 mm) and deep (≥7 mm) pockets. In the probiotic lozenges group, there were also significantly more pockets converting from ≥4 mm at baseline to ≤3 mm at 24 weeks (67 ± 18% versus 54 ± 17%) and less sites in need for surgery (4 ± 4% versus 8 ± 6%). However, the probiotic products did not influence the microbiological counts of the periodontopathogens. CONCLUSION: The adjunctive consumption of L. reuteri lozenges after re‐instrumentation improved the PPD reduction, without an impact on pocket colonization with periodontopathogens.
format Online
Article
Text
id pubmed-6973056
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69730562020-01-27 A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial Laleman, Isabelle Pauwels, Martine Quirynen, Marc Teughels, Wim J Clin Periodontol Periodontal Therapy AIM: To examine the adjunctive effect of a Lactobacillus reuteri probiotic (ATCC PTA 5289 & DSM 17938) on the re‐instrumentation of residual pockets. MATERIALS AND METHODS: This randomized, double‐blind, placebo‐controlled study included 39 previously non‐surgically treated periodontitis patients. A re‐instrumentation was carried out, and probiotic and/or placebo drops were applied according to the study protocoll. Patients afterwards received lozenges to use 2×/day for 12 weeks. Probing pocket depth (PPD), recession, bleeding on probing and plaque levels were analysed, next to the microbiological impact. RESULTS: No effects of the probiotic drops could be found. However, after 24 weeks, the overall PPD in the probiotic lozenges group (2.64 ± 0.33 mm) was significantly lower compared to the control lozenges (2.92 ± 0.42 mm). This difference was even more pronounced in moderate (4–6 mm) and deep (≥7 mm) pockets. In the probiotic lozenges group, there were also significantly more pockets converting from ≥4 mm at baseline to ≤3 mm at 24 weeks (67 ± 18% versus 54 ± 17%) and less sites in need for surgery (4 ± 4% versus 8 ± 6%). However, the probiotic products did not influence the microbiological counts of the periodontopathogens. CONCLUSION: The adjunctive consumption of L. reuteri lozenges after re‐instrumentation improved the PPD reduction, without an impact on pocket colonization with periodontopathogens. John Wiley and Sons Inc. 2019-11-14 2020-01 /pmc/articles/PMC6973056/ /pubmed/31520543 http://dx.doi.org/10.1111/jcpe.13198 Text en © 2019 The Authors. Journal of Clinical Periodontology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Periodontal Therapy
Laleman, Isabelle
Pauwels, Martine
Quirynen, Marc
Teughels, Wim
A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
title A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
title_full A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
title_fullStr A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
title_full_unstemmed A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
title_short A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
title_sort dual‐strain lactobacilli reuteri probiotic improves the treatment of residual pockets: a randomized controlled clinical trial
topic Periodontal Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973056/
https://www.ncbi.nlm.nih.gov/pubmed/31520543
http://dx.doi.org/10.1111/jcpe.13198
work_keys_str_mv AT lalemanisabelle adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT pauwelsmartine adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT quirynenmarc adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT teughelswim adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT lalemanisabelle dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT pauwelsmartine dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT quirynenmarc dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial
AT teughelswim dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial